Top

BY Ron Gilmore

Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) have published guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. These guidelines outline...

BY Scott Merville

A study led by MD Anderson found the investigational drug quizartinib prolongs overall survival for patients with a deadly form of acute myeloid...

BY Ron Gilmore

A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the TRACTION platform inhibits a vital...

BY Ron Gilmore

The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia (ALL) than standard chemotherapy, a Phase III clinical trial involving 101 centers in 21 countries showed.

The study, led by The University of Texas MD Anderson Cancer Center, revealed that median survival was 7.7 months for patients receiving blinatumomab, with median survival of 7.7 months...

acute lymphoblastic leukemia

BY Ron Gilmore

Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T...